Auna SA (AUNA) AI Stock Analysis
AUNA AI stock analysis summary
AI ResearchAuna SA is a healthcare provider operating hospitals, clinics, and health plans across Mexico, Peru, and Colombia. Over the trailing twelve months, the company generated $4.67B in revenue, though net profit margin was 0.4%. With total debt of $3.72B and a debt-to-equity ratio of 2.01, debt management remains a prominent factor alongside its trailing P/E ratio of 88.7x.
- Market cap
- $394.0M
- Revenue (TTM)
- $4.67B
- P/E
- 88.7x
- 1Y return
- -16.7% S&P 500 16.8%
- Avg. target
- $6.99 31.3% vs last close
Bull case
- Free cash flow generation remained positive at $161.8M in FY2025, backed by $242.8M in operating cash flow.
- Analyst consensus expects next fiscal year revenue to expand 5.1% to $5.11B with an EPS growth rebound of 26.9%.
- The company's EV-to-EBITDA multiple of 6.2x represents a discount compared to the US-listed Healthcare peer median of 12.0x.
Bear case
- Total debt of $3.72B significantly exceeds cash of $480.5M, driving a debt-to-equity ratio of 2.01.
- Trailing twelve-month net profit margin is thin at 0.4%, leaving the trailing P/E ratio elevated at 88.7x.
- Over the trailing 1-year period, Auna shares declined 16.7% while the S&P 500 gained 16.8%.
What Auna does
Headquartered in Luxembourg and founded in 1989, Auna SA operates an extensive network of hospitals and clinics across Mexico, Peru, and Colombia. The company provides healthcare delivery tailored to regional needs, operating medical hubs equipped with advanced technologies and staffed by skilled medical professionals. In Peru, Auna is renowned for its prepaid healthcare plans offering comprehensive coverage and access to diverse medical specialties. In Mexico, the company also offers specialized dental and vision plans. Auna employs 14,796 people and focuses on advancing healthcare accessibility, health outcomes, and patient satisfaction across key Latin American markets.
Growth and profitability
Auna grew revenue from $1.92B in FY2021 to $2.45B in FY2022 and $3.88B in FY2023, reaching $4.39B in FY2024. For FY2025, revenue was flat at $4.39B, completing a 5-year revenue CAGR of 24.9% from FY2020 to FY2025. Gross margin shifted from 35.7% in FY2021 to 37.9% in FY2025, while operating margin rose from 6.7% to 14.4%. Net income was positive at $110.3M in FY2024 and $97.6M in FY2025, recovering from net income of -$253.9M in FY2023. In the latest quarter ended June 30, 2026, quarterly revenue increased 13.2% year-over-year, while quarterly earnings fell 64.0%.
Balance sheet and cash flow
As of June 30, 2026, Auna held $480.5M in cash and short-term investments against total debt of $3.72B, leaving net debt at $3.24B. The balance sheet reflects shareholders' equity of $1.86B, total assets of $7.78B, a current ratio of 1.08, and a debt-to-equity ratio of 2.01. In FY2025, the company generated $242.8M in operating cash flow and $161.8M in free cash flow, while allocating $81.1M to capital expenditures. Over 5 years, the company's share count increased 50.7%.
Valuation and performance
Auna trades at a market capitalization of $394.0M and an enterprise value of $1.31B. Its trailing P/E ratio of 88.7x sits well above the 24.6x median of its US-listed Healthcare peers. Conversely, its price-to-sales ratio of 0.1x and EV-to-EBITDA of 6.2x compare to peer medians of 4.1x and 12.0x, respectively. The stock closed at $5.32 on October 16, 2026, standing 4.0% above its 200-day average. Over the past year, Auna shares fell 16.7%, trailing the S&P 500 return of 16.8%.
What analysts expect
Wall Street coverage includes 4 Strong Buy, 1 Buy, and 2 Hold ratings. The mean price target of $6.99 implies an upside of 31.3% relative to the last close of $5.32. For the fiscal year ending December 31, 2026, analysts estimate revenue of $4.86B and EPS of $0.85, reflecting an EPS decrease of 32.6%. The company beat EPS estimates in 2 of the last 4 quarters. The next earnings date is scheduled for November 17, 2026.
Key risks and what to watch
- Quarterly earnings fell 64.0% year-over-year in the period ended June 30, 2026, reflecting bottom-line pressure.
- Net debt of $3.24B combined with a current ratio of 1.08 heightens sensitivity to interest costs and refinancing terms.
- Auna has exceeded consensus EPS targets in only 2 of the past 4 quarters, signaling quarterly forecasting variability.
- A 50.7% expansion in share count over 5 years indicates past equity dilution.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this AUNA AI stock analysis
This page is an AI-written research summary of Auna SA (AUNA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: AUNA income statement, AUNA balance sheet, AUNA key metrics, AUNA analyst forecast, AUNA chart. See the AUNA stock overview for the latest quote and news.
AUNA AI stock analysis FAQ
What healthcare services does Auna SA provide?
Auna SA operates a network of hospitals and clinics in Mexico, Peru, and Colombia. It also provides comprehensive prepaid healthcare plans in Peru along with specialized dental and vision plans in Mexico.
What is Auna's current debt burden?
As of June 30, 2026, Auna held $3.72B in total debt and $480.5M in cash and short-term investments, resulting in net debt of $3.24B. Its debt-to-equity ratio is 2.01.
Does Auna pay a dividend?
Auna does not pay a dividend. The company used its operating cash flow in FY2025 to fund $81.1M in capital expenditures and support its core healthcare operations.
What are analysts' price targets for AUNA stock?
Analysts have established a mean price target of $6.99, which represents a 31.3% premium over the last close of $5.32. The ratings distribution consists of 4 Strong Buy, 1 Buy, and 2 Hold ratings.